AC Immune announced positive clinical and regulatory progress in Q3 2026, including FDA Fast Track designation and IND clearance for its Parkinson’s drug ACI-7104, which showed strong safety and immunogenicity in Phase 2 trials. The company also reported promising Phase 1 safety results for its NLRP3 inhibitor ACI-19764 and selected a lead candidate for its Morphomer small molecule program targeting alpha-synuclein. With CHF 73.9 million in cash, AC Immune is well-funded through Q1 2028 and expects further clinical data for ACI-7104 by year-end and ACI-19764 in early 2027.
AC Immune's Q3 2026 update provides context for health sector activity on Pluang. For readers following health stocks, as of Nov 04, 2026 18:41 WIB, 118 of 150 priced US health-sector stocks rose while 24 fell. Notable movers include Revvity Inc (RVTY) at USD 173.82 with a 6.32% increase and 100% buy orders, Nuvation Bio Inc (NUVB) at USD 4.98 up 6.18%, and Canopy Growth Corp (CGC) at USD 0.75 rising 6.13% with 100% buy orders.
Sutro Biopharma, a clinical-stage oncology company specializing in antibody drug conjugates (ADCs), announced its participation in several investor conferences in November and December 2026, including events hosted by Stifel, Truist Securities, UBS, ...
etoro has agreed to acquire LB Finanzas, a leading Argentine all-in-one financial app, to strengthen its presence in Latin America's fast-growing fintech market. LB Finanzas offers integrated investing and payment solutions, catering to Argentine ret...
JD.com announced it will publish its unaudited financial results for the third quarter of 2026 on November 17, before the U.S. market opens. The company's management will hold a conference call the same day to discuss the results, providing investors...
KE Holdings Inc., a major online and offline housing platform in China, will announce its unaudited financial results for the third quarter of 2026 on November 16 before the U.S. market opens. The company will host an earnings conference call at 7:00...
Dimensional Fund Advisors Ltd. filed a Form 8.3 disclosure revealing it holds a 1.27% stake in Prologis Inc as of November 3, 2026. This disclosure is part of regulatory requirements under the Takeover Code for investors holding 1% or more in relevan...
